Efficacy and Safety of Meloxicam (Mobicox®) in Mexican Population With Rheumatic Diseases

N/ACompletedNCT02184039

Boehringer Ingelheim12,687 enrolled

Overview

Study to evaluate the efficacy and safety of meloxicam (Mobicox®) in Mexican population with rheumatic diseases.

Study Type

OBSERVATIONAL

Enrollment

12,687

Conditions

Osteoarthritis

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * none Exclusion Criteria: * Hypersensitivity to meloxicam or to other NSAIDS * History of asthma, angioedema or urticaria secondary to NSAIDS * Pregnancy or lactation * Recent or current history of peptic ulcer disease, severe renal failure, severe hepatic failure * Age below of 12 years.

Outcomes

Primary Outcomes

Change in intensity of the symptoms measured with a four-point scale

Time frame: Baseline, 30 and 90 days

Secondary Outcomes

Degree of satisfaction evaluated with a six point numerical rating scale

Time frame: up to 90 days

Number of patients with adverse events

Time frame: up to 90 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.